Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2022-03-30 Governance Information
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Appendix 4G & Corporate Governance Statement 24 pages 525.9KB
Governance Information Classification · 100% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It includes detailed disclosures about corporate governance practices, board charters, diversity policies, board evaluations, and other governance-related information for the financial year ended 31 December 2021. The document explicitly states it is a corporate governance statement approved by the board and is separate from the annual report. The content aligns with governance disclosures rather than financial results or management changes. Therefore, this document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification.
2022-03-30 English
IRX granted wholesale licenses for scheduled substances 2 pages 174.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30th March 2022 regarding InhaleRx Ltd being granted wholesale licences to sell and supply poisons or controlled substances, including medicinal cannabis. It is a regulatory announcement about licensing approval from the Victorian Department of Health & Human Services. The document is short (1987 characters) and does not contain financial statements, management discussion, or detailed financial data. It is not a report, earnings release, or management commentary. It is an update on a regulatory/licensing event relevant to the company's operations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-03-29 English
Preliminary Final Report 13 pages 471.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 February 2022 providing preliminary financial results for the year ended 31 December 2021. It includes detailed financial statements such as the statement of profit or loss, statement of financial position, statement of changes in equity, and statement of cash flows. The document also references an Appendix 4E Preliminary final report and mentions that the attached financial information is being audited. The length of the document (15,000 characters) and the inclusion of comprehensive financial data and analysis indicate this is a full financial report rather than a brief announcement or certification. The content aligns with an Interim / Quarterly Report (IR) as it is a preliminary report for the full year but not the final audited annual report (10-K). The document is not a full Annual Report (10-K) since it is preliminary and mentions the audit is ongoing. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). FY 2021
2022-02-27 English
Quarterly Appendix 4C Cash Flow Report 5 pages 228.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities for the quarter ended 31 December 2021. It includes actual financial data such as cash flows, reconciliation of cash and cash equivalents, payments to related parties, and financing facilities. The document is approximately 10,780 characters long, which is substantial and contains substantive financial data. The presence of quarterly financial statements and cash flow details aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or certification but a full quarterly financial report. Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2021
2022-01-30 English
Quarterly Activities Report 4 pages 554.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'QUARTERLY ACTIVITIES, CASHFLOW REPORT and OPERATIONS UPDATE' for the quarter ended 31 December 2021. It contains operational highlights, cash flow figures, appointment of an executive director, clinical development updates, product launches, commercial agreements, payments to directors, and use of funds during the quarter. The presence of detailed financial data for the quarter, including cash reserves, net cash used in operating activities, and specific expenditure items, indicates this is a comprehensive quarterly report rather than a brief announcement or a simple earnings release. The document length (5898 characters) and content support classification as an Interim / Quarterly Report (IR). Q2 2021
2022-01-30 English
InhaleRx Ltd appoints Executive Director 2 pages 172.4KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 29th December 2021 regarding the appointment of an Executive Director following the resignation of the CEO. It details the new director's background, remuneration, and role. There is no financial data, no report or presentation attached, and no mention of voting results or other regulatory filings. The content clearly relates to a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3347 characters, which is consistent with a typical management announcement rather than a full report or regulatory filing.
2021-12-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.